NewEdge Wealth LLC Acquires Shares of 4,928 Natera, Inc. $NTRA

NewEdge Wealth LLC bought a new position in Natera, Inc. (NASDAQ:NTRA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,928 shares of the medical research company’s stock, valued at approximately $1,338,000.

Other institutional investors also recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Natera during the 2nd quarter valued at $2,962,770,000. Coatue Management LLC raised its holdings in shares of Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after acquiring an additional 2,463,008 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. Norges Bank acquired a new stake in Natera during the fourth quarter valued at $372,398,000. Finally, JPMorgan Chase & Co. grew its stake in Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insiders Place Their Bets

In related news, Director Herm Rosenman sold 16,530 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the sale, the director directly owned 4,250 shares in the company, valued at approximately $1,062,500. The trade was a 79.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at $24,035,465.29. The trade was a 27.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 181,045 shares of company stock worth $41,330,968 in the last three months. 5.05% of the stock is owned by insiders.

Natera Price Performance

Natera stock opened at $332.03 on Friday. Natera, Inc. has a one year low of $157.43 and a one year high of $333.56. The company’s fifty day moving average price is $274.24 and its two-hundred day moving average price is $229.39. The company has a market capitalization of $47.86 billion, a price-to-earnings ratio of -244.14 and a beta of 1.51.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Royal Bank Of Canada upped their target price on Natera from $275.00 to $350.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Evercore reiterated an “outperform” rating and set a $300.00 price target on shares of Natera in a report on Monday, July 6th. Robert W. Baird set a $348.00 price target on Natera in a research note on Friday, August 7th. TD Cowen increased their price objective on Natera from $325.00 to $340.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Canaccord Genuity Group set a $375.00 price objective on shares of Natera in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $319.38.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.